Skip to main content
Fig. 6 | Journal of Hematology & Oncology

Fig. 6

From: Augmentation of the anticancer activity of CYT997 in human prostate cancer by inhibiting Src activity

Fig. 6

Dasatinib improves CYT997 efficacy in suppression of prostate cancer metastasis. a–d The tumor-bearing mice described in Fig. 5 were sacrificed on day 42 after treatment, and the lungs and livers were dissected and removed. The metastatic nodules on the pulmonary or hepatic surface were counted (a, c) (n = 5), and the tissue sections were stained with HE for pathological analysis (b, d). Black arrows in b indicate tumor foci in the mice lung, and white stars in d indicate tumor foci in the mice liver. e NSG mice were injected via intracardiac with 1 × 106 luciferase-containing PC3 cells before treatment. Tumor progression was monitored by examining luminescence in Xenogen IVIS-200 In Vivo Imaging System. *p < 0.05; **p < 0.01

Back to article page